---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-028818"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2024-07-23T23:59:59+00:00"
generated_at: "2026-05-31T18:06:30.776508+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Evofem licenses Phexxi to Pharma 1 for Middle East; closes $500K private placement with Aditxt

## Summary
- Exclusive 5-year license for Phexxi in UAE, Kuwait, Saudi Arabia, Qatar and other Middle East countries.
- Pharma 1 to file UAE regulatory submission in Q3 2024; UAE contraceptive market projected $185.1M by 2030.
- Pharma 1 pays cost-to-manufacture plus fee; must maintain at least 4 months of inventory at all times.
- Evofem closed $500K private placement with Aditxt via 500 shares of Series F-1 Preferred Stock.
- Merger with Aditxt targeting September 30, 2024 closing; amended merger agreement dated July 2024.

## SEC filing metadata
- accession: 0001493152-24-028818
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2024-07-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315224028818/0001493152-24-028818-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315224028818/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-028818
- JSON: https://secwatch.observer/filing/0001493152-24-028818.json
- Plain text: https://secwatch.observer/filing/0001493152-24-028818.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.